Background: To determine the role of fibroblast growth factor (FGF)-19 and FGF21 and the
endocrine FGFs receptor system in the metabolic alterations that manifest in HIV-1–infected …

Objective: HIV-1-infected patients with lipodystrophy show insulin resistance, dyslipidemia
and other signs of metabolic syndrome. Fibroblast growth factor-21 (FGF21) is a novel …

Background Antiretroviral therapy has significantly improved prognosis in treatment against
HIV infection, however, prolonged exposure is associated to cardiovascular diseases …

Objectives Dyslipidaemia, insulin resistance, metabolic syndrome and HIV/HAART-
associated lipodystrophy syndrome (HALS) are common comorbidities in HIV-1-infected …

Objective Few studies have investigated irisin and FGF 21 to elucidate the role of these
hormones to regulate 'beiging'in HIV‐infected patients. Design Fifty HIV‐infected subjects …

Background Fibroblast growth factor (FGF)-21 is a novel regulator of glucose and lipid
metabolism. Recently, increased FGF-21 mRNA expression in muscle was found in patients …

Recently new evidence about fibroblast growth factor 21 (FGF21) highlights the
opportunities to use this molecule in new pharmaceutical formulations to combat type 2 …

Objective Patients with lipodystrophy (LD) suffer from loss of subcutaneous adipose tissue
accompanied by dysregulation of several adipocyte-secreted factors. However, regulation of …

Background and Aims We tested the effects of recombinant insulin-like growth factor-I (IGF-I)
in an adipocyte model of HIV lipodystrophy and in an open label study on body composition …

Plasma biomarkers that reflect energy balance disorders in people living with HIV (PLWH)
remain limited. Growth differentiation factor 15 (GDF15) abundance in plasma of mice and …